China Brucellosis Market Research Report By species (Brucella suis, B

China Brucellosis Market Overview

As per MRFR analysis, the China Brucellosis Market Size was estimated at 21.35 (USD Million) in 2023.The China Brucellosis Market is expected to grow from 23.25(USD Million) in 2024 to 77.17 (USD Million) by 2035. The China Brucellosis Market CAGR (growth rate) is expected to be around 11.523% during the forecast period (2025 - 2035).

Key China Brucellosis Market Trends Highlighted

The rising prevalence of brucellosis in livestock and rising consumer awareness of food safety are the main factors propelling the market in China. In rural and pastoral areas, where cattle production plays a major role in the economy, brucellosis is particularly common.

Government efforts to manage the disease through vaccination campaigns, information campaigns, and more stringent regulations have increased as a result. Recognizing the effects on public health, the Chinese government has put strategic measures into place to lower the infection rate and stop outbreaks, highlighting the significance of managing brucellosis in livestock.

This market has a lot of untapped potential, especially for the creation of locally relevant diagnostic instruments and efficient vaccines. Biotechnology research and development can result in novel products that improve animal health overall and disease control in particular.

A favorable climate exists for private companies to enter the market with innovative solutions that complement national health initiatives as the government makes investments in veterinary public health and animal disease prevention.

Government agencies and commercial businesses are increasingly working together to improve illness reporting and surveillance systems, according to recent trends. Strong monitoring and control methods for brucellosis are urgently needed, as China's urbanization and shifting consumer patterns are influencing the need for safer animal products.

In order to promote a comprehensive strategy for the prevention and control of brucellosis in the area, improved channels of communication and information sharing are also essential in bridging the gap between farmers and health authorities.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

China Brucellosis Market Drivers

Rising Incidence of Brucellosis in Livestock

In China, the increasing prevalence of brucellosis among livestock is a prominent driver for the China Brucellosis Market. According to reports from the Ministry of Agriculture and Rural Affairs, China's livestock population has faced notable increases in brucellosis outbreaks, especially in regions such as Inner Mongolia and Xinjiang.

The frequency of livestock infection has been estimated to grow at an annual rate of 12%, which has a direct correlation to the rising demand for diagnostic tests and vaccines used in the prevention of the disease.

According to the Chinese Veterinary Medical Association, the control of brucellosis in livestock is critical for both public health and agricultural productivity, which in turn encourages investments and innovations in the brucellosis treatment market.

This increasing concern among governmental organizations and the agricultural sector will ultimately drive growth in the China Brucellosis Market, leading to enhanced product offerings and improved management strategies.

Government Initiatives for Disease Control

The Chinese government's proactive initiatives to control brucellosis outbreaks serve as a significant driver for the China Brucellosis Market. The State Council of China has implemented strict regulations and guidelines aimed at reducing incidences of brucellosis through awareness campaigns and legislation focused on prevention.

In recent years, the government has allocated increased funding for Research and Development of brucellosis control measures, rising by approximately 15% annually.

As a result, these initiatives facilitate the growth of pharmaceutical companies that develop vaccines and diagnostic tools specifically targeting brucellosis, aligning with the national health agendas. The response from governmental bodies and the consequent rise in funding play a vital role in shaping the dynamics of the China Brucellosis Market.

Growing Awareness Among Farmers and Consumers

The growing awareness of brucellosis among both farmers and consumers in China represents a crucial driver influencing the China Brucellosis Market.

Educational programs supported by the Ministry of Agriculture are increasingly reaching rural communities, where farmers are being equipped with knowledge about disease prevention and control strategies, notably in regions that have historically faced high infection rates.

Recent surveys indicated that approximately 70% of farmers in endemic regions now recognize the health benefits associated with vaccination and regular testing. This heightened awareness is not only leading to higher vaccine uptake but also enhancing diagnostic order volumes, ultimately driving the demand for brucellosis management solutions within the market.

Technological Advancements in Diagnostics

Technological advancements in diagnostic testing for brucellosis are driving growth in the China Brucellosis Market. Innovations, such as the development of rapid testing kits that deliver results within hours, have emerged from collaborations with esteemed research institutions in China like the Chinese Academy of Agricultural Sciences.

These advancements have led to a significant reduction in time and resources needed for disease confirmation, with adoption rates for these technologies estimated to rise by over 20% in the next five years.

Enhanced diagnostic capabilities enable quicker responses to outbreaks, fostering improvement in overall herd health management, and subsequently bolster the market for brucellosis-related products in China.

China Brucellosis Market Segment Insights

Brucellosis Market species Insights

The China Brucellosis Market is intricately segmented by species, with Brucella suis, B. abortus, and B. melitensis playing significant roles in the dynamics of the market. Brucella suis, often associated with swine, is particularly concerning for both agricultural health and food safety, given China's substantial pig farming industry.

Its prevalence in domestic animals poses a notable risk for zoonotic transmission to humans, thereby impacting public health initiatives and surveillance measures. B. abortus primarily impacts cattle and is crucial for the dairy industry, which is vital in China’s agricultural economy; managing this species is essential to secure both animal health and produce quality.

B. melitensis is highly pathogenic and is primarily associated with sheep and goats, making it a focal point in regions with a robust livestock sector, as it can lead to significant economic losses through livestock morbidity.

The collective focus on these species highlights their importance within the market, as controlling their prevalence is necessary for maintaining livestock health and ensuring the safety of the food supply chain. The demand for advanced diagnostics and vaccines continues to grow, driven by increasing concerns over Brucellosis outbreaks in livestock.

Enhanced surveillance and management strategies become fundamental, particularly as urbanization and agricultural practices evolve. With the increasing emphasis on agricultural biosecurity and public health in China, the insights into these species become crucial for fostering better health outcomes in both animals and humans.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

China Brucellosis Market Key Players and Competitive Insights

The competitive landscape of the China Brucellosis Market reflects a complex interplay between various manufacturers and service providers focused on tackling the growing prevalence of brucellosis in livestock and its implications for public health.

This market is characterized by a burgeoning demand for vaccines, diagnostic kits, and effective treatment options aimed at reducing infection rates among livestock such as cattle, goats, and sheep. The Chinese government has put efforts into tackling this zoonotic disease through policy initiatives and funding for research and development.

Competitive insights reveal key players who are not only innovating in vaccine technology but also enhancing their production capabilities to meet both domestic and international market needs. Awareness campaigns and increased veterinary outreach programs significantly contribute to the market dynamics, thereby shaping competitive strategies among companies.

In the context of the China Brucellosis Market, the China Animal Husbandry Industry Company has established a stronghold with its comprehensive portfolio of veterinary vaccines and diagnostic solutions. This company's strengths lie in its extensive R&D capabilities and its commitment to producing high-quality, effective products specifically designed to combat brucellosis in livestock.

With a widespread distribution network and strategic partnerships with local veterinary services, the China Animal Husbandry Industry Company has successfully penetrated various regions across China, resulting in a robust presence in the market.

Their focus on educating farmers about brucellosis management further bolsters their reputation and reinforces customer loyalty, paving the way for future growth and innovation in the sector.

Xiamen Egens Biotechnology stands as a prominent player in the China Brucellosis Market, specializing in the development and commercialization of innovative testing kits and therapeutic agents. Known for its strong emphasis on biotechnology solutions, Xiamen Egens has carved a niche for itself by offering reliable and effective products that focus on early detection and prevention of brucellosis.

The company’s strengths are highlighted by its significant investment in R&D, resulting in advanced diagnostics that enhance animal health monitoring. Market presence is also reinforced through collaborations and strategic partnerships that allow Xiamen Egens to broaden its outreach and distribution channels across China.

The company has been active in merging and acquiring smaller biotech firms, which accelerates its innovation pipeline and expands its product offerings, ensuring that it remains competitive in the evolving landscape of animal health solutions focused on brucellosis.

Key Companies in the China Brucellosis Market Include:

• China Animal Husbandry Industry Company


• Xiamen Egens Biotechnology


• Guangzhou Liyuan Biotechnology


• Shenzhen Lianhe Biological Technology


• Beijing Wantai Biological Pharmacy


• Hengshui Shengxin Biological Pharmaceutical


• Wuhan Institute of Biological Products


• Jiangsu Kubo BioTechnology


• China National Pharmaceutical Group


• Zhejiang Kehua BioEngineering

China Brucellosis Market Developments

The China Brucellosis Market has seen noteworthy developments recently, particularly with a focus on controlling and managing brucellosis outbreaks, which have impacted both public health and the livestock industry. In recent months, the Ministry of Agriculture and Rural Affairs in China has emphasized the importance of vaccination and surveillance measures in livestock to mitigate the disease.

Companies such as China Animal Husbandry Industry Company and Beijing Wantai Biological Pharmacy are leading efforts in Research and Development for effective vaccines against Brucellosis.

Additionally, there has been notable growth in the market, enhancing valuations of firms like Xiamen Egens Biotechnology and Guangzhou Liyuan Biotechnology, attributed to rising awareness and regulatory support for disease management.

Furthermore, in July 2023, Shenzhen Lianhe Biological Technology announced an acquisition of certain assets from Jiangsu Kubo Biotechnology, indicating consolidation trends within the sector. This acquisition is aligned with the broader strategic goals to enhance capabilities in vaccine development and distribution.

Major incidents in the past few years have prompted regulatory mandates for improved biosecurity measures, influencing the operational landscape for firms like Hengshui Shengxin Biological Pharmaceutical and Wuhan Institute of Biological Products.

China Brucellosis Market Segmentation Insights

Brucellosis Market species Outlook

• Brucella suis


• B. abortus


• B. melitensis

Report Attribute/Metric Source:	Details
MARKET SIZE 2023	21.35(USD Million)
MARKET SIZE 2024	23.25(USD Million)
MARKET SIZE 2035	77.17(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)	11.523% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2024
MARKET FORECAST UNITS	USD Million
KEY COMPANIES PROFILED	China Animal Husbandry Industry Company, Xiamen Egens Biotechnology, Guangzhou Liyuan Biotechnology, Shenzhen Lianhe Biological Technology, Beijing Wantai Biological Pharmacy, Hengshui Shengxin Biological Pharmaceutical, Wuhan Institute of Biological Products, Jiangsu Kubo BioTechnology, China National Pharmaceutical Group, Zhejiang Kehua BioEngineering
SEGMENTS COVERED	species
KEY MARKET OPPORTUNITIES	Rising livestock vaccination programs, Increasing demand for diagnostic tests, Growing awareness of zoonotic diseases, Enhanced government health initiatives, Expansion of research and development.
KEY MARKET DYNAMICS	increasing incidence rates, government awareness programs, livestock health regulations, vaccination initiatives, diagnostic technology advancements
COUNTRIES COVERED	China